Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Rognan

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
British Journal of Pharmacology|May 30, 2007
Chemogenomic approaches to rational drug designD Rognan
Pharmaceutica Acta Helvetiae|December 23, 1998
From peptides to peptidomimetics: design of nonpeptide ligands for major histocompatibility proteinsS Krebs, D Rognan
Bioorganic & Medicinal Chemistry Letters|March 27, 2001
Customized versus universal scoring functions: application to class I MHC-peptide binding free energy predictionsA Logean, A Sette, D Rognan
Journal of Peptide Science : an Official Publication of the European Peptide Society|October 31, 1998
Binding of rationally designed non-natural peptides to the human leukocyte antigen HLA-B*2705S Krebs, G Folkers, D Rognan
SAR and QSAR in Environmental Research|April 29, 2006
Design of nevirapine derivatives insensitive to the K103N and Y181C HIV-1 reverse transcriptase mutantsP Saparpakorn, S Hannongbua, D Rognan
Journal of Medicinal Chemistry|December 22, 2000
Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinationsC Bissantz, G Folkers, D Rognan
Acta Crystallographica. Section D, Biological Crystallography|July 1, 1995
Molecular dynamics and structure-based drug design for predicting non-natural nonapeptide binding to a class I MHC proteinL Scapozza, D Rognan, G Folkers, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 31, 1995
Rational design of nonnatural peptides as high-affinity ligands for the HLA-B*2705 human leukocyte antigenD Rognan, L Scapozza, G Folkers, et al.
Journal of Computer-Aided Molecular Design|March 29, 2001
NMR-restrained docking of a peptidic inhibitor to the N-terminal domain of the phosphoenolpyruvate:sugar phosphotransferase enzyme ID Rognan, S Mukhija, G Folkers, et al.
European Journal of Biochemistry|August 15, 1992
Molecular dynamics study of a complex between the human histocompatibility antigen HLA-A2 and the IMP58-66 nonapeptide from influenza virus matrix proteinD Rognan, N Zimmermann, G Jung, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
British Journal of Pharmacology|May 30, 2007
Chemogenomic approaches to rational drug designD Rognan
Pharmaceutica Acta Helvetiae|December 23, 1998
From peptides to peptidomimetics: design of nonpeptide ligands for major histocompatibility proteinsS Krebs, D Rognan
Bioorganic & Medicinal Chemistry Letters|March 27, 2001
Customized versus universal scoring functions: application to class I MHC-peptide binding free energy predictionsA Logean, A Sette, D Rognan
Journal of Peptide Science : an Official Publication of the European Peptide Society|October 31, 1998
Binding of rationally designed non-natural peptides to the human leukocyte antigen HLA-B*2705S Krebs, G Folkers, D Rognan
SAR and QSAR in Environmental Research|April 29, 2006
Design of nevirapine derivatives insensitive to the K103N and Y181C HIV-1 reverse transcriptase mutantsP Saparpakorn, S Hannongbua, D Rognan
Journal of Medicinal Chemistry|December 22, 2000
Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinationsC Bissantz, G Folkers, D Rognan
Acta Crystallographica. Section D, Biological Crystallography|July 1, 1995
Molecular dynamics and structure-based drug design for predicting non-natural nonapeptide binding to a class I MHC proteinL Scapozza, D Rognan, G Folkers, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 31, 1995
Rational design of nonnatural peptides as high-affinity ligands for the HLA-B*2705 human leukocyte antigenD Rognan, L Scapozza, G Folkers, et al.
Journal of Computer-Aided Molecular Design|March 29, 2001
NMR-restrained docking of a peptidic inhibitor to the N-terminal domain of the phosphoenolpyruvate:sugar phosphotransferase enzyme ID Rognan, S Mukhija, G Folkers, et al.
European Journal of Biochemistry|August 15, 1992
Molecular dynamics study of a complex between the human histocompatibility antigen HLA-A2 and the IMP58-66 nonapeptide from influenza virus matrix proteinD Rognan, N Zimmermann, G Jung, et al.
Pageof 4